Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASH 2023 | SATISFY: mitapivat in patients with erythrocyte membranopathies

Kevin Kuo • 10 Dec 2023

ASH 2023

Anemias Non-Malignant Mitapivat

SATISFY

Kevin Kuo, MD, MSc, FRCPC, University Health Network, Toronto, Canada, introduces the SATISFY study (NCT05935202), a prospective, single-arm Phase II trial that will assess the safety and efficacy of mitapivat, a pyruvate kinase-R (PKR) activator, in adult patients with erythrocyte membranopathies. Patients with membranopathy or congenital dyserythropoietic anemia type II (CDA II) will be enrolled in the trial. Dr Kuo outlines the eligibility criteria, planned study protocol, and primary and secondary outcomes of the study. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Luspatercept in patients with HbE/β‑thalassemia: a subgroup analysis from the BELIEVE study

Kevin Kuo • 10 Dec 2023

Thalassemia highlights at ASH 2023: novel therapies, trial updates & the value of precision medicine

Kevin Kuo et al. • 11 Dec 2023

Durable symptom improvement in NTD thalassemia treated with luspatercept in the BEYOND trial

Kevin Kuo • 10 Dec 2023

PB-04 in beta thalassemia intermedia and SCD

Kevin Kuo • 10 Dec 2023

Related Videos

The MDT in the new era of gene therapy for hemoglobinopathies

Mattia Algeri • 15 Apr 2024

Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases

Rita Beier • 15 Apr 2024

Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH

Carlo Dufour • 15 Apr 2024

A two-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemia

Antonio Risitano • 16 Apr 2024